Traduction de «for their potential » (Néerlandais → Français) :

TERMINOLOGIE

afwijkend(e) | elektro-oculogram [EOG] | afwijkend(e) | elektromyogram [EMG] | afwijkend(e) | elektroretinogram [ERG] | afwijkend(e) | respons op zenuwstimulatie | afwijkend(e) | visually evoked potential [VEP]
Anomalies (de):électromyogramme [EMG] | électro-oculogramme [EOG] | électrorétinogramme [ERG] | potentiels évoqués visuellement | réponse à une stimulation nerveuse

potentiëring | versterking
potentiation/potentialisation | augmentation de l'action d'un médicament par l'absorption d'un second

potentie | kracht
1) puissance sexuelle - 2) efficacité | 1) puissance sexuelle - 2) d'un médicament

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The primary concern of doctors, pharmacists, and other health professionals is informing their patients and drawing their attention to the fact that it is of crucial importance to use the correct dosage (e.g. by drawing their attention to the potential side effects of a treatment once it has been started and explaining to them that antidepressants need a few weeks to take effect).
La plus grande préoccupation des médecins, pharmaciens et autres prestataires de soins de santé est d’informer les patients sur l’importance d’une posologie correcte et de les informer (par exemple en attirant l’attention sur des possibles effets secondaires d’un traitement entamé et en expliquant que les antidépresseurs ne commencent à être effectifs qu’au bout de quelques semaines).

Getting closer – targeted therapies work, but need help to fulfill their potential, Nature Editorial, 2011; 473, 253–254 Een korte inleiding over de nieuwste ontwikkelingen in de gepersonaliseerde geneeskunde, met internationale casestudies.
Getting closer – targeted therapies work, but need help to fulfil their potential, Nature Editorial, 2011; 473, 253–254 Brève présentation des dernières avancées en médecine personnalisée, avec des études de cas internationales

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

Two US regulatory submissions completed in late 2009 – Tasigna (cancer) and Gilenia (FTY720, multiple sclerosis) – were recognized in the first quarter of 2010 for their potential patient benefits.
Deux demandes d’homologation ont été déposées fin 2009 aux Etats-Unis pour Tasigna (cancer) et Gilenia (FTY720, sclérose en plaques). Les bénéfices potentiels de ces médicaments pour les malades ont été reconnus au premier trimestre 2010.

In preparation for potential pandemics, such as avian flu, we have taken steps to protect the health of our associates and their families, to guarantee uninterrupted supplies of our life-saving drugs to patients, and to ensure business continuity.
Afin de prévenir une telle éventualité – par exemple, une pandémie de grippe aviaire – nous avons pris des mesures en vue de protéger la santé de nos collaborateurs et de leur famille, de garantir la livraison des médicaments qui maintiennent des malades en vie, et d’assurer la continuité de nos activités.

It is, however, clear that although the Ethics Committees and the FAMHP arrive at their decisions independently, there is potentially a considerable amount of overlap between the interpretation of preclinical and medical aspects.
It is, however, clear that although the Ethics Committees and the FAMHP arrive at their decisions independently, there is potentially a considerable amount of overlap between the interpretation of preclinical and medical aspects.

- At the end of the follow-up and potential referral, the suicidal individuals are contacted again by telephone (provided they have agreed to this) after a period of one month / three months / six months / a year, in order to maintain contact and assess their general evolution.
- au terme du suivi et de l’orientation éventuelle, un contact téléphonique est repris avec le suicidant (pour autant qu’il ait manifesté son accord) à l’échéance d’un mois / trois mois / six mois / un an afin de maintenir le lien et jauger l’évolution générale de la personne.